Following a spate of patient deaths in clinical trials testing modified T cells for the treatment of cancer, researchers work to reduce the treatment’s toxicity without sacrificing efficacy.

Tumors’ mutations can encode the seeds of their own destruction, in the form of immunogenic peptides recognized by T cells.

Neoantigens may serve as valuable targets for new immunotherapies.

The genomics pioneer shares the sessions she most looks forward to at this year’s American Association for Cancer Research annual meeting.

Billionaire Silicon Valley entrepreneur Sean Parker donates $250 million to unite the cancer research community around the common goal of developing new immunotherapies.

Understanding cancer’s relationship with the human microbiome could transform immune-modulating therapies.

In recent years, research has demonstrated that microbes living in and on the mammalian body can affect cancer risk, as well as responses to cancer treatment.

Teenager Lauren Bendesky turned her cancer diagnosis on its head, using herself as a research subject to test potential therapies.

Clinical cases link immune changes to a cancer’s spread through the body, but find no role for so-called “driver” mutations.

The biotech firm Celgene inks a huge collaboration deal with Juno Therapeutics to develop and commercialize new cancer immunotherapies.